Diagnosed with a rare condition at age 18, Mackenzie Wilmoth has recovered, and she's leading the efforts to help those ...

September 13, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present a ...

Management of large abdominal wall desmoid tumours is complicated due to the unpredictable behaviour of desmoids and the need for laborious reconstruction of the abdominal wall after wide local ...

The fund is Bain’s fourth and follows several recent acquisitions of some of its portfolio companies, among them Jnana ...

Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to ...

J.P. Morgan analyst Anupam Rama maintained a Buy rating on Springworks Therapeutics (SWTX – Research Report) today and set a price target ...

Its product pipeline includes vactosertib drug, to treat gastric and pancreatic cancer, desmoid sarcoma, colorectal and bladder cancer, non-small cell lung carcinoma (NSCLC), multiple myeloma and ...

Foscenvivint is under development for the treatment of HCV or HBV or NASH-induced decompensated cirrhosis, leukemia such as acute myeloid leukemia (AML), neuroendocrine tumors, ch ...

Jazz Pharmaceuticals and Zymeworks, Inc. have announced that Jazz and Zymeworks BC, Inc. (a Zymeworks subsidiary) have entered into a licensing agreement, under which Jazz is to acquire the ...

The FDA approved SpringWorks’ Ogsiveo (nirogacestat) for treating adult patients with desmoid tumors who require systemic treatment in November 2023. Following the FDA nod, not only Ogsiveo ...